| MediciNova and the Hercules Market of the Osaka Securities Exchange announced the initiation of a Phase Ib clinical trial, by holding the Investigator's Meeting, to evaluate the safety of MN-221 at planned escalating doses in patients with stable, moderate to severe chronic obstructive pulmonary disease. COPD exacerbations represents the second respiratory indication for which MediciNova is currently evaluating MN-221. :theflyonthewall.com |
